-DOCSTART- -X- O
The -X- _ O
last -X- _ O
5 -X- _ O
years -X- _ O
have -X- _ O
been -X- _ O
marked -X- _ O
by -X- _ O
profound -X- _ O
innovation -X- _ O
in -X- _ O
the -X- _ O
targeted -X- _ O
treatment -X- _ O
of -X- _ O
chronic -X- _ B-Patient
lymphocytic -X- _ I-Patient
leukemia -X- _ I-Patient
( -X- _ I-Patient
CLL -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
indolent -X- _ I-Patient
lymphomas. -X- _ I-Patient
Using -X- _ O
CLL -X- _ O
as -X- _ O
a -X- _ O
case -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
present -X- _ O
a -X- _ O
timeline -X- _ O
and -X- _ O
overview -X- _ O
of -X- _ O
the -X- _ O
current -X- _ O
treatment -X- _ O
landscape -X- _ O
for -X- _ O
the -X- _ O
radiologist -X- _ B-Outcome
, -X- _ O
including -X- _ O
an -X- _ O
overview -X- _ O
of -X- _ O
clinical -X- _ B-Outcome
and -X- _ I-Outcome
radiological -X- _ I-Outcome
features -X- _ I-Outcome
of -X- _ I-Outcome
CLL -X- _ I-Outcome
, -X- _ O
discussion -X- _ O
of -X- _ O
the -X- _ O
targeted -X- _ B-Outcome
agents -X- _ I-Outcome
themselves -X- _ I-Outcome
, -X- _ O
and -X- _ O
the -X- _ O
role -X- _ B-Outcome
of -X- _ I-Outcome
imaging -X- _ I-Outcome
in -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
toxicity -X- _ I-Outcome
assessment. -X- _ I-Outcome
The -X- _ O
goal -X- _ O
is -X- _ O
to -X- _ O
familiarize -X- _ O
the -X- _ O
radiologist -X- _ B-Outcome
with -X- _ O
multiple -X- _ O
Food -X- _ B-Intervention
and -X- _ I-Intervention
Drug -X- _ I-Intervention
Administration -X- _ I-Intervention
( -X- _ I-Intervention
FDA -X- _ I-Intervention
) -X- _ I-Intervention
-approved -X- _ I-Intervention
targeted -X- _ I-Intervention
agents -X- _ I-Intervention
used -X- _ O
in -X- _ O
this -X- _ O
setting -X- _ O
and -X- _ O
associated -X- _ O
adverse -X- _ O
events -X- _ O
which -X- _ O
are -X- _ O
commonly -X- _ O
observed -X- _ O
in -X- _ O
this -X- _ O
patient -X- _ O
population -X- _ O
. -X- _ O

